ULK1

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

Retrieved on: 
Thursday, April 11, 2024
UNC, Doctor of Philosophy, BECN1, Autophagy, ERK, Pathology, HGF, AKT, Athira Pharma, Alzheimer's disease, Disease, Excitotoxicity, Toxicity, Shikimate pathway, ULK1

The original research article, “ Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease ,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics.

Key Points: 
  • The original research article, “ Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease ,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics.
  • “These data continue to highlight the potential of fosgonimeton as a novel therapeutic approach for Alzheimer's disease targeting multiple facets of its complex pathophysiology,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.
  • “These preclinical data published in a peer-reviewed journal suggest that fosgonimeton counteracts aspects of AD pathology that lead to neurodegeneration.
  • These findings bolster our confidence in the Phase 2/3 LIFT-AD trial evaluating fosgonimeton in mild-to-moderate AD, with data anticipated in the second half of 2024.”

Endeavor BioMedicines Closes $101M Series B Financing to Advance Clinical-Stage Precision Medicine Pipeline

Retrieved on: 
Monday, February 7, 2022
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Prevalence, Apoptosis, Pharming, Myofibroblast, Nutrient, KRAS, Neoplasm, Hedgehog, Board, Research, Squamous cell carcinoma, Twitter, Cancer, IND, Program, Technology, Patient, Safety, ULK1, Drug resistance, Endeavour, CEO, Lung, IPF, Entrepreneurship, Autophagy, Idiopathic pulmonary fibrosis, LinkedIn, Recycling, BCC, PTCH1, Fibrosis, Pharmaceutical industry, Vaccine, Biomedicine

Endeavor BioMedicines , a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.

Key Points: 
  • Endeavor BioMedicines , a clinical-stage biotechnology company targeting the core drivers of terminal diseases including oncology and fibrosis, today announced the completion of a $101 million Series B financing, led by Ally Bridge Group and Avidity Partners.
  • Endeavor is currently enrolling patients in an open label Phase 2 clinical trial in oncology ( www.clinicaltrials.gov identifier NCT05199584 ).
  • Endeavor plans to complete IND-enabling studies and advance the program into the clinic in the next year.
  • Endeavor BioMedicines is a clinical-stage precision medicine company targeting the core drivers of multiple terminal diseases, including oncology and fibrosis.

Deciphera Presents Preclinical Data from DCC-3116 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021
Biotechnology, Pharmaceutical, Health, NASDAQ, Private Securities Litigation Reform Act, Large-cell lung carcinoma, Pharmacokinetics, EGFR, Autophagosome, Drug resistance, GIST, Conference, BRAF, LLC, COVID-19, Survival, LinkedIn, Growth, Safety, Cancer, Feedback, United States, RAS, KRAS, SEC, Melanoma, ULK1, U.S. Securities and Exchange Commission, Gefitinib, ULK, MEK, AACR, Autophagy, United, Â, RAF, Afatinib, Patient, Neoplasm, ULK2, View, Colorectal cancer, NRAS, Phosphorylation, Pharmaceutical industry, DCC-3116, Deciphera Pharmaceuticals, DCC-3116, DECIPHERA PHARMACEUTICALS

These results reinforce the broad potential of autophagy inhibition as a mechanism to address the challenge of drug resistance in the treatment of cancer.

Key Points: 
  • These results reinforce the broad potential of autophagy inhibition as a mechanism to address the challenge of drug resistance in the treatment of cancer.
  • The poster presentation is available on-demand via the meeting website and on the Companys website at www.deciphera.com/presentations-publications .
  • Deciphera is a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer.
  • Deciphera, the Deciphera logo, QINLOCK, and the QINLOCK logo are registered trademarks of Deciphera Pharmaceuticals, LLC.

CurePSP funds four new grants to advance treatment of prime of life neurodegeneration

Retrieved on: 
Friday, September 10, 2021

NEW YORK, Sept. 10, 2021 /PRNewswire/ -- CurePSP has awarded Venture Grants totaling $320,000 to scientists at Harvard Medical School, Columbia University, UT Southwestern Medical Center, and UCLA.

Key Points: 
  • NEW YORK, Sept. 10, 2021 /PRNewswire/ -- CurePSP has awarded Venture Grants totaling $320,000 to scientists at Harvard Medical School, Columbia University, UT Southwestern Medical Center, and UCLA.
  • Symptoms include loss of motor control, behavioral disinhibition, cognitive impairment, and difficulties in swallowing and speech.
  • They are termed "prime of life" neurodegeneration because, unlike Alzheimer's disease, they frequently strike in middle age.
  • Currently, there is no effective treatment or cure for these diseases, which affect more than 150,000 people in the U.S. alone.